Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALENT
2024-511878-67-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tiragolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety and Feasibility. Planned start Oct 2024; status: authorised.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-511878-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511878-67-00.